AbbVie (ABBV) Stock Forecast & Price Target

Compare

23,468 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

15 Buy

8 Hold

0 Sell

Based on 23 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$254.35

▲(13.48% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $254.35 with a high forecast of $289.00 and a low forecast of $218.00. The average price target represents a 13.48% change from the last price of $224.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","200":"$200","230":"$230","260":"$260","290":"$290"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$289.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":254.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$254.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":218,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$218.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,200,230,260,290],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.49,233.1446153846154,237.79923076923077,242.45384615384617,247.10846153846154,251.76307692307694,256.41769230769233,261.0723076923077,265.7269230769231,270.38153846153847,275.03615384615387,279.6907692307692,284.3453846153846,{"y":289,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.49,230.47923076923078,232.46846153846155,234.45769230769233,236.44692307692307,238.43615384615384,240.42538461538462,242.4146153846154,244.40384615384616,246.39307692307693,248.38230769230768,250.37153846153845,252.36076923076922,{"y":254.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.49,227.68307692307692,226.87615384615384,226.06923076923078,225.2623076923077,224.45538461538462,223.64846153846153,222.84153846153848,222.0346153846154,221.2276923076923,220.42076923076922,219.61384615384617,218.80692307692308,{"y":218,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":171.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$289.00

Average Price Target$254.35

Lowest Price Target$218.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rajesh Kumar

HSBC

$265

Buy

18.23%

Upside

Reiterated

01/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Alexandria Hammond

Wolfe Research

$275

Hold

22.70%

Upside

Downgraded

01/08/26

AbbVie downgraded to Peer Perform from Outperform at Wolfe ResearchAbbVie downgraded to Peer Perform from Outperform at Wolfe Research

Michael Yee

UBS

$220→$240

Hold

7.08%

Upside

Reiterated

01/07/26

AbbVie: Premium Valuation, Strong Long-Duration Growth, but Balanced Risk/Reward Supports Hold Rating

Luisa Hector

Berenberg Bank

$270

Buy

20.47%

Upside

Reiterated

01/06/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Geoff Meacham

Citi

$235

Hold

4.85%

Upside

Reiterated

01/05/26

AbbVie (ABBV) Gets a Hold from Citi

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

David Amsellem

Piper Sandler

$289

Buy

28.94%

Upside

Reiterated

12/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Gavin Clark-Gartner

Evercore ISI

$222→$233

Buy

3.96%

Upside

Reiterated

12/17/25

AbbVie (ABBV) Gets a Buy from Evercore ISI

Jason Gerberry

Bank of America Securities

$233

Hold

3.96%

Upside

Reiterated

12/15/25

AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

Louise Chen

Scotiabank

$280

Buy

24.93%

Upside

Reiterated

12/15/25

AbbVie (ABBV) Receives a Buy from Scotiabank

Terence Flynn

Morgan Stanley

$261→$269

Buy

20.02%

Upside

Reiterated

12/12/25

AbbVie price target raised to $269 from $261 at Morgan StanleyAbbVie price target raised to $269 from $261 at Morgan Stanley

Mohit Bansal

Wells Fargo

$260

Buy

16.00%

Upside

Reiterated

12/10/25

LargeCap Biopharma Outlook—We Like It

Elmar Kraus

DZ BANK AG

$237

Hold

5.74%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Evan Seigerman

BMO Capital

$240→$258

Buy

15.11%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO Capital

Chris Schott

J.P. Morgan

$250→$260

Buy

16.00%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rajesh Kumar

HSBC

$265

Buy

18.23%

Upside

Reiterated

01/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Alexandria Hammond

Wolfe Research

$275

Hold

22.70%

Upside

Downgraded

01/08/26

AbbVie downgraded to Peer Perform from Outperform at Wolfe ResearchAbbVie downgraded to Peer Perform from Outperform at Wolfe Research

Michael Yee

UBS

$220→$240

Hold

7.08%

Upside

Reiterated

01/07/26

AbbVie: Premium Valuation, Strong Long-Duration Growth, but Balanced Risk/Reward Supports Hold Rating

Luisa Hector

Berenberg Bank

$270

Buy

20.47%

Upside

Reiterated

01/06/26

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Geoff Meacham

Citi

$235

Hold

4.85%

Upside

Reiterated

01/05/26

AbbVie (ABBV) Gets a Hold from Citi

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

David Amsellem

Piper Sandler

$289

Buy

28.94%

Upside

Reiterated

12/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Gavin Clark-Gartner

Evercore ISI

$222→$233

Buy

3.96%

Upside

Reiterated

12/17/25

AbbVie (ABBV) Gets a Buy from Evercore ISI

Jason Gerberry

Bank of America Securities

$233

Hold

3.96%

Upside

Reiterated

12/15/25

AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

Louise Chen

Scotiabank

$280

Buy

24.93%

Upside

Reiterated

12/15/25

AbbVie (ABBV) Receives a Buy from Scotiabank

Terence Flynn

Morgan Stanley

$261→$269

Buy

20.02%

Upside

Reiterated

12/12/25

AbbVie price target raised to $269 from $261 at Morgan StanleyAbbVie price target raised to $269 from $261 at Morgan Stanley

Mohit Bansal

Wells Fargo

$260

Buy

16.00%

Upside

Reiterated

12/10/25

LargeCap Biopharma Outlook—We Like It

Elmar Kraus

DZ BANK AG

$237

Hold

5.74%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Evan Seigerman

BMO Capital

$240→$258

Buy

15.11%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO Capital

Chris Schott

J.P. Morgan

$250→$260

Buy

16.00%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

18/26 ratings generated profit

Average Return

+2.44%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +2.44% per trade.

3 Months

xxx

Success Rate

22/28 ratings generated profit

Average Return

+7.94%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +7.94% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

18/18 ratings generated profit

Average Return

+21.83%

reiterated a buy rating 2 months ago

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.83% per trade.

2 Years

xxx

Success Rate

26/26 ratings generated profit

Average Return

+34.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 19 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 254.35.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.32 with a range of $2.62 to $3.52. The previous quarter’s EPS was $1.86. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $16.39B with a range of $16.23B to $17.01B. The previous quarter’s sales results were $15.78B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 254.35.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 13.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 15 buy ratings, 8 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 254.35. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $289.00 ,the lowest forecast is $218.00. The average price target represents 13.48% Increase from the current price of $224.13.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Detailed List of Analyst Forecasts